BUENA, N.J., March 23, 2015 /PRNewswire/ -- IGI Laboratories,
Inc. (NYSE MKT: IG), a New
Jersey-based specialty generic pharmaceutical company, today
announced that it has appointed John
Celentano to its Board of Directors. Mr. Celentano
will also serve on the Company's Audit Committee.
Jason Grenfell-Gardner, President
and CEO of the Company, commented, "We are thankful John has agreed
to join our Board of Directors. John's extensive experience
at Bristol-Myers Squibb, and his recent engagements as a consultant
to companies at various stages of growth in the pharmaceutical
industry will be a great asset to IGI and its Board of
Directors." Mr. Grenfell-Gardner continued, "We look forward
to working with John, as we continue on our mission to be a leader
in the specialty generic prescription drug markets."
Mr. Celentano currently works as an advisor to the
pharmaceutical industry. He has over 30 years of experience
in the pharmaceutical industry, having held various senior
leadership positions at Bristol-Myers Squibb
including: President, Bristol-Myers Squibb
Healthcare Group (Mead Johnson Nutrition, ConvaTec, and
Medical Imaging) and Regional President roles in Emerging
Markets/Asia Pacific,
Latin America/Canada, and
UK/Northern Europe. He
serves on the Boards of privately held JJ White Inc. and
YourEncore Inc. He is Vice-Chairman of CMMB, an international
nonprofit healthcare organization. Mr. Celentano holds a
B.A. from the University of Delaware and a MBA from Drexel University.
About IGI Laboratories, Inc.
IGI Laboratories is a specialty generic drug development and
manufacturing company. Our mission is to be a leader in the
specialty generic prescription drug market.
Forward-Looking Statements
This press release includes certain "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995. These forward-looking statements include, but are not
limited to, plans, objectives, expectations and intentions, and
other statements contained in this press release that are not
historical facts and statements identified by words such as "plan,"
"believe," "continue", "should" or words of similar meaning.
Factors that could cause actual results to differ materially from
these expectations include, but are not limited to: our inability
to meet current or future regulatory requirements in connection
with existing or future ANDAs; our inability to achieve
profitability; our failure to obtain FDA approvals as anticipated;
our inability to execute and implement our business plan and
strategy; the potential lack of market acceptance of our products;
our inability to protect our intellectual property rights; changes
in global political, economic, business, competitive, market and
regulatory factors; and our inability to complete successfully
future product acquisitions. These statements are based on
our current beliefs or expectations and are inherently subject to
various risks and uncertainties, including those set forth under
the caption "Risk Factors" in IGI Laboratories, Inc.'s most recent
Annual Report on Form 10-K, Quarterly Reports on Form 10-Q
and other periodic reports we file with the Securities and Exchange
Commission. IGI Laboratories, Inc. does not undertake any
obligation to update any forward-looking statements contained in
this document as a result of new information, future events or
otherwise, except as required by law.
Logo -
http://photos.prnewswire.com/prnh/20130827/MM70487LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/igi-laboratories-inc-appoints-john-celentano-to-board-of-directors-300054327.html
SOURCE IGI Laboratories, Inc.